INOTREM
Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today it received funding from the Crohn’s & Colitis Foundation’s IBD Ventures under a program to accelerate research and development that aim to improve the quality of life for patients with IBD. The funding will support the development of a new therapeutic approach in IBD focusing on the TREM-1 pathway.
The funding follows a R&D collaboration between Inotrem, and the Crohn’s & Colitis Foundation announced in April 2022. The R&D collaboration seeks to pave the way of a personalized medicine approach in IBD patients based on TREM-1. Under the terms of the agreement, Inotrem has access to data and bio-samples from Foundation’s IBD Plexus®, which is the largest IBD database in the US with data from over 25,000 patients. Lasting over 18 months, the project will be a cornerstone in the design of Inotrem’s first-in-human clinical study with INO-02.
There are today 10 million people worldwide suffering from IBD, and the need for new therapeutic options remains very strong. Approximately 30% of patients are unresponsive to existing therapies and even among the initial responders, in up to 10% the drugs lose efficacy over time. For a decade, Inotrem has been elucidating the biology of TREM-1 as a regulator of the immune response in both acute as well as chronic inflammatory diseases. TREM-1 is a potential important contributor to IBD pathophysiology and targeting this pathway may offer a new treatment option for IBD patients with immune dysregulation.
“We are grateful for the support of such a well-respected organization as The Crohn’s & Colitis Foundation. This funding will help us to expand our patented technology platform centered around the TREM-1 pathway and dedicated to developing new therapies for chronic inflammatory syndromes next to our existing modalities for acute diseases,” indicates Sven Zimmermann, CEO of Inotrem.
“Beyond the financial support, this is a strong recognition of Inotrem’s scientific leadership regarding the role of the TREM-1 pathway in inflammatory processes as well as our robust therapeutic approaches targeting that biological target,” says Marc Derive, Chief Scientific Officer and Cofounder of Inotrem.
About Inotrem
Inotrem S.A. is an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, nangibotide, with potential applications in a number of therapeutic indications such as septic shock and myocardial infarction. In parallel, Inotrem has also launched another program to develop a new therapeutic modality targeting chronic inflammatory diseases. The company was founded in 2013 by Dr Jean-Jacques Garaud, a former head of research and early development at the Roche Group, Prof. Sebastien Gibot and Dr Marc Derive. Inotrem is supported by leading European and North American investors. www.inotrem.com
About the Crohn’s & Colitis Foundation
The Crohn's & Colitis Foundation is the leading non-profit organization focused on both research and patient support for inflammatory bowel disease (IBD), with the mission of curing Crohn's disease and ulcerative colitis, and of improving the quality of life of the millions of Americans living with IBD. The Foundation’s work is dramatically accelerating the research process through investment in research initiatives, while also providing extensive educational and support resources for patients and their families, medical professionals, and the public. For more information, visit crohnscolitisfoundation.org, call 888-694-8872, or email info@crohnscolitisfoundation.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230109005241/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SymphonyAI and Matas Group are Redefining Health & Beauty in the Nordics With AI7.1.2026 06:07:00 CET | Press release
Matas Group partners with SymphonyAI to streamline category management, elevate the customer experience, and accelerate growth across key Nordic markets In the ever-evolving health and beauty landscape, Matas Group continues to set the standard for innovation and customer care. As the largest retailer in its sector across Denmark, Sweden, Finland, and Norway, Matas Group is committed to delivering unified, data-driven experiences to millions of customers — both online and in-store. That commitment now takes a leap forward as Matas selects SymphonyAI, a global leader in Vertical AI platforms, as its partner to modernize category management across the entire enterprise. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107270530/en/ Exterior of a Matas Group retail store in Scandinavia. The leading Nordic health and beauty retailer is expanding its category management capabilities through a new partnership with SymphonyAI. Fol
Lenovo Supercharges Enterprise AI with the Launch of Agentic AI and Lenovo xIQ to Deliver Full-Lifecycle Hybrid AI at Scale7.1.2026 02:00:00 CET | Press release
Lenovo Agentic AI gives organizations the governance, tools, advice, and ongoing support needed to deploy and manage production-ready AI agents faster and smarter – turning AI ambition into measurable impact.Three new Lenovo xIQ delivery platforms strengthen Lenovo’s Hybrid AI Advantage™ by delivering the automation and governance enterprises need to scale AI with confidence. Lenovo today announced the next phase of its Hybrid AI Advantage™ with the launch of Lenovo Agentic AI, a new full-lifecycle enterprise solution for creating, deploying, and managing AI agents, and Lenovo xIQ a new suite of AI-native delivery platforms designed to simplify, accelerate, and operationalize AI across the enterprise. This evolution extends Lenovo’s established Hybrid AI Advantage™ from a foundational AI architecture to a more complete, lifecycle-driven approach for deploying and scaling AI across the enterprise. Lenovo Hybrid AI Advantage™ is Lenovo’s end-to-end enterprise AI portfolio, providing the
Lenovo Defines the Next Era of Hybrid AI with Personalized, Perceptive, and Proactive AI Portfolio at Tech World @ CES 20267.1.2026 02:00:00 CET | Press release
Lenovo announces Lenovo and Motorola Qira personal agentic AI across devices, new Motorola flagship smartphones, expanded portfolio of AI PCs, visionary proofs of concept including agentic-native wearables, and revolutionary inferencing servers alongside breakthroughs in AI technologies for FIFA, Formula 1®, and entertainment. Today at Tech World @ CES 2026 at Sphere in Las Vegas, Lenovo unveiled the boldest innovations yet for the future of Hybrid AI, introducing a new personal AI super agent, AI PCs and smartphones, proofs of concept including agentic-native wearables, next-generation enterprise AI infrastructure, and breakthrough industry collaborations in entertainment and sports. Building on years of AI innovation across devices, infrastructure, solutions, and services, Lenovo demonstrated how AI is now personal, perceptive, proactive, and everywhere. Lenovo’s new offerings adapt to individuals and organizations, operating as digital twins to orchestrate actions across ecosystems
Lenovo Teams with NVIDIA on Gigawatt AI Factories Program to Accelerate Enterprise AI7.1.2026 02:00:00 CET | Press release
High-velocity solutions enable AI cloud providers to achieve faster time-to-first token, accelerating ROI and production-ready AI servicesPartner acceleration program combines solutions, services and manufacturing to deliver AI at giga-scale, enabling seamless scaling to millions of GPUs for next-generation workloads Today at Tech World @ CES 2026 at Sphere in Las Vegas, Lenovo (HKSE: 992) (ADR: LNVGY) unveiled the Lenovo AI Cloud Gigafactory with NVIDIA, expandingand reinforcing its partnership with NVIDIA through a shared commitment to accelerating hybrid AI adoption across personal, enterprise and public AI platforms. During his keynote,Lenovo Chairman and CEO Yuanqing Yang, joined by NVIDIA founder and CEO Jensen Huang, debuted this new gigawatt-scale AI factory program as a major advancement that enables AI cloud providers to bring next generation AI workloads and applications online faster, moving customers from creation to production at unprecedented scale. “In the AI era, value
Lenovo Unveils Breakthrough Personal AI Super Agent, Novel Adaptive Concepts, and Next-Gen Device Innovations Spanning Mobile, Gaming, Consumer and Commercial Portfolios at CES 20267.1.2026 02:00:00 CET | Press release
Advanced AI Devices, Software and Concepts Propel Lenovo’s Smarter AI for All Vision Forward At CES® 2026, Lenovo™ unveiled a sweeping lineup of innovations across its wide portfolio, introducing smarter new personal AI experiences, first-of-its-kind proofs-of-concept, and major updates across its gaming, mobile, consumer, and commercial devices. From ThinkPad™ to ThinkBook™, ThinkCentre™, Yoga™, IdeaPad™, Legion, and Motorola, Lenovo is showing how its Smarter AI for All vision is coming to life through more adaptive devices, bold new form factors, and AI software experiences designed to fit naturally into everyday life. The showcase is headlined by the debut of Lenovo and Motorola Qira, a new type of cross-device AI super agent that’s a Personal Ambient Intelligence System. “With Lenovo and Motorola Qira, we are entering a new era of personal AI: one designed around users, built on trust, and shaped by their control,” said Luca Rossi, President of Intelligent Devices Group, Lenovo. “
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom